Genetic and clinical factors best to predict late recurrence in estrogen receptor POS breast cancer
A new analysis has provided a comprehensive comparison of scores designed to predict which women with oestrogen-receptor positive breast cancer are at high risk of recurrence beyond five years after diagnosis, and may benefit ...
Cancer
May 02, 2013 |
not rated yet |
0
Ability to metabolize tamoxifen affects breast cancer outcomes, study confirms
For nearly a decade, breast cancer researchers studying the hormone therapy tamoxifen have been divided as to whether genetic differences in a liver enzyme affect the drug's effectiveness and the likelihood breast cancer ...
Cancer
Dec 27, 2012 |
not rated yet |
0
|
Anastrozole and fulvestrant combo better than single drug for metastatic breast cancer
Results of a SWOG clinical trial published August 2 in the New England Journal of Medicine show the combination of anastrozole and fulvestrant extended the median survival time of women with hormone receptor-positive metast ...
Cancer
Aug 01, 2012 |
not rated yet |
0
Afinitor approved for advanced breast cancer
(HealthDay) -- Afinitor (everolimus) has been approved in combination with the drug exemestane to treat postmenopausal women with advanced hormone-receptor positive, HER2-negative breast cancer, the U.S. Food ...
Medications
Jul 23, 2012 |
not rated yet |
0
Estrogen-targeting drug combo may help prevent lung cancer
A combination of drugs that target estrogen production significantly reduced the number of tobacco carcinogen-induced lung tumors in mice, according to results from a preclinical study.
Cancer
Jan 09, 2012 |
not rated yet |
0
Anti-estrogen combo better than single drug for hormone-sensitive breast cancer
Post-menopausal women with hormone receptor-positive metastatic breast cancer may have a new treatment option that could lengthen their lives, according to results of a study by the SWOG clinical trials network that were ...
Cancer
Dec 07, 2011 |
not rated yet |
0
|
